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330 The Journal of Thoracic and CardioObjective: Cardiac surgery with cardiopulmonary bypass induces both systemic and
local inflammatory responses implicated in the pathogenesis of myocardial dysfunc-
tion. Multifactorial perioperative sources of myocardial injury complicate under-
standing of the molecular mechanisms involved. By using microarray technology,
this study examines myocardial gene expression responses to cardiopulmonary
bypass in the absence of cardioplegic arrest and ischemia-reperfusion injury.
Methods: We used a unique rat model of cardiopulmonary bypass in which ster-
notomy, direct operations on the heart, aortic crossclamping, and cardioplegic arrest
were not performed. Hearts from 6 animals randomized to either 90 minutes of
cardiopulmonary bypass or sham control animals were used to perform cDNA
microarray analyses of 2343 genes. Real-time quantitative polymerase chain reac-
tion was used to confirm the microarray results for a subset of genes.
Results: Compared with sham-operated control animals, myocardium from animals
undergoing cardiopulmonary bypass revealed 42 differentially expressed genes.
Upregulated genes include the transcription activator nuclear factor B, adhesion
molecules (vascular cell adhesion molecule 1 and P-selectin), and interleukin 6
receptor subunits; downregulated genes include transforming growth factor  re-
ceptor 2, tissue inhibitor of metalloproteinase 3, and mitogen-activated protein
kinase 1. Distinct proinflammatory gene cascades were confirmed by means of
category overrepresentation analysis.
Conclusions: This study represents an initial report on the use of microarray
technology to elucidate cardiac transcriptional programs in response to cardiopul-
monary bypass–specific injury in vivo. These preliminary findings, combined with
future functional genomic studies superimposing ischemia and reperfusion and other
inflammatory stimuli, should improve our understanding of the molecular regulatory
networks involved in myocardial responses to injury and aid in the development of
novel cardioprotective and perfusion strategies.
Almost 50 years after the first clinical application of cardiopulmonary bypass(CPB), the pathophysiology of injury-induced myocardial dysfunction aftercardiac operations with CPB remains poorly characterized. Numerous
experimental and clinical studies have demonstrated that CPB leads to a systemic
inflammatory response triggered by bioincompatibility of blood-contacting surfaces,
surgical trauma, ischemia and reperfusion, and endotoxemia.1 It is increasingly
recognized that this generalized inflammation is implicated in the pathogenesis of
post-CPB cardiovascular dysfunction, including myocardial stunning, ischemia, and
-adrenergic desensitization.2,3 In addition to the well-described changes in circu-
lating levels of proinflammatory mediators associated with CPB, it has been estab-
lished that the heart itself participates in the host inflammatory response to cardiac
vascular Surgery ● August 2005
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Psurgery,4 but underlying molecular regulatory mechanisms
remain poorly characterized.
Transcriptional profiling has emerged as a powerful tool
for delineating complex patterns of tissue-specific gene ex-
pression in response to severe systemic stimuli and injury,5
and several recent studies have used microarray technology
to examine the global myocardial stress response during
cardiac surgery.6,7 However, interpretation of such gene
expression analyses is complicated by the activation of
biologic cascades stemming from the combined insults of
cardioplegic arrest, ischemia and reperfusion, and direct
tissue injury in addition to the effects of CPB. Therefore, to
begin dissecting the molecular mechanisms underlying
myocardial responses to specific CPB-initiated injury, we
used a unique model of rat CPB in which median sternot-
omy, direct operations on the heart, aortic crossclamping,
and cardioplegic arrest were not performed. Specifically, we
tested the hypothesis that nonpulsatile normothermic CPB
alone (in the absence of cardioplegic arrest and ischemia-
reperfusion) activates both systemic proinflammatory re-
sponses and myocardial inflammatory gene cascades. Such
Figure 1. Schematic diagram of the surgical preparat
Nellgard B, Pineda J, Newman MF, Warner DS, Gro
neurocognitive dysfunction in the rat. Anesthesiology.
Williams & Wilkins.)differential gene expression profiling in response to differ-
The Journal of Thoracient myocardial stressors or insults might provide mechanis-
tic insights that aid in the development and evaluation of
novel cardioprotective and perfusion strategies.
Methods
Surgical Preparation and CPB
All animal experiments were performed in compliance with the
“Guide for the Care and Use of Laboratory Animals.”8 Details of
the closed-chest rat CPB model used in the current study (Figure
1) have been previously described.9 Adult male Sprague-Dawley
rats (325-375 g; Harlan, Indianapolis, Ind) were anesthetized with
isoflurane, orotracheally intubated, and mechanically ventilated
(40% O2/balance N2). Surgical preparation involved cannulation
of the ventral tail artery (arterial inflow) by using a 20-gauge
catheter and, after systemic heparinization (150 U/kg), insertion of
a 4.5F multiorifice cannula through the external jugular vein into
the right atrium (venous outflow). The anesthetic was then con-
verted to fentanyl (150 g/kg administered intravenously), diaze-
pam (2 mg/kg administered intravenously), and pancuronium (0.2
mg/kg administered intravenously). Animals were randomized to
90 minutes of normothermic, nonpulsatile CPB (n  3) or to serve
as sham-operated control animals (n  3) after undergoing iden-
nd rat CPB apparatus. (From Mackensen GB, Sato Y,
P. Cardiopulmonary bypass induces neurologic and
;95:1485-91. Reproduced with permission of Lippincottion a
cott H
2001tical surgical preparation and anesthetic regimen. The CPB circuit
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Cole-Parmer Instrument Co, Vernon Hills, Ill), and a membrane
oxygenator (Micro neonatal oxygenator; Cobe Cardiovascular,
Inc, Arvada, Colo) connected through 1.6-mm internal diameter
silicone tubing (Tygon, Cole-Parmer Instrument Co). The CPB
circuit was primed with approximately 40 mL of whole blood
obtained before the start of the experiment from 2 heparinized (100
U per rat, intravenous) donor rats that were exsanguinated during
isoflurane-induced anesthesia; the activated clotting time was
maintained at greater than 450 seconds for the duration of CPB.
All sham-operated animals were given equivalent heparin doses.
The targeted CPB flow was 160 to 180 mL · kg1 · min1,
corresponding to normal cardiac output in the rat,10 and the inflow
temperature was maintained at 37.5°C by using a circulating water
bath system. Whole hearts were then snap-frozen in liquid nitrogen
and stored at 80°C.
Quantification of Plasma Cytokine Levels
Characterization of the systemic inflammatory response in this closed-
chest small-animal model of CPB was performed by quantifying
plasma cytokine levels (interleukin [IL] 6 and IL-10) at the end of the
experimental period (90 minutes). Evaluations were performed in
duplicate by using commercially available enzyme-linked immu-
nosorbent assay kits (Pierce Endogen, Inc, Rockford, Ill), according to
the manufacturer’s protocol. Changes in IL-6 and IL-10 levels
(plasma concentration after surgical intervention minus baseline
plasma concentration) were compared between experimental groups
by using the Wilcoxon rank sum test in SAS (version 8; SAS Institute,
Cary, NC). Physiologic parameters were compared between groups
by using repeated-measures analysis of variance, followed by New-
man-Keuls tests for multiple comparisons as appropriate.
RNA Isolation, Labeling, and cDNA Array
Hybridization
Total RNA was extracted from tissue samples (whole hearts) by
using the Trizol method (Gibco BRL Life Technologies, Rock-
ville, Md). Genomic DNA contamination was removed by means
of digestion of RNA samples with DNase I (Ambion, Inc, Austin,
Tex) and confirmed by means of polymerase chain reaction (PCR)
using glyceraldehyde-phosphate dehydrogenase (GAPDH)–spe-
cific primers. Radiolabeled cDNA probes were synthesized by
means of reverse transcription of total RNA (5 g) in the presence
of -[32P]dCTP and hybridized to Atlas Rat cDNA expression
nylon arrays (Rat 1.2 and 1.2II; Clontech, BD Biosciences, Palo
Alto, Calif) for 12 hours at 68°C, according to the manufacturer’s
protocol. The arrays were washed in 2 saline sodium citrate/1%
sodium dodecylsulfate at 68°C for 2 hours and in 0.1 saline
sodium citrate/0.5% sodium dodecylsulfate at 68°C for 30 minutes
and exposed to low-energy storage phosphor screens (Molecular
Dynamics, Sunnyvale, Calif) for 24 hours.
Microarray Data Analysis
Phosphor images were acquired with a PhosphorImager Storm
system (Molecular Dynamics) at 100 m resolution. Hybridized
spots intensities on the microarray were quantified with Image-
Quant (Molecular Dynamics) and AtlasImage version 2.02 (Clon-
tech, BD Biosciences) software. Background intensities were sub-
tracted from the hybridization signal, and genes with background-
332 The Journal of Thoracic and Cardiovascular Surgery ● Auguadjusted intensities of less than twice the background value were
filtered out. The annotation of genes spotted on the Clontech Atlas
Rat v1.2 (I and II) microarray was updated by querying the
National Center for Biotechnology Information (NCBI) Unigene
database and using the 2370 GenBank identifiers provided by the
manufacturer. To remove systematic intensity differences among
arrays caused by differences in film exposure, labeling efficiency,
and hybridization-washing conditions, a variance stabilizing trans-
formation and normalization (VSN) method11 was applied to each
hybridization image as follows:
VSN (yki) arsinh (ai biyki),
where yki is the background-corrected intensity of gene k on array i,
and ai and bi are affine parameters optimized by the VSN algorithm
by using maximum-likelihood estimations for array i. All data anal-
ysis was in compliance with the Minimum Information About Mi-
croarray Experiments standards (http://www.mged.org/Workgroups/
MIAME/miame.html), and the complete data sets were deposited in
the NCBI Gene Expression Omnibus database (http://www.ncbi.nlm-
.nih.gov/geo/) under accession numbers GSM14486-14497 for the
individual samples and GSE921, GSE922, and GSE924 for the ex-
perimental series. Detection of differentially expressed genes was
performed by using the method developed by Lonnstedt and Speed12
in the statistical package R (http://lib.stat.cmu.edu/R/CRAN). A
Bayesian B-score defined as
B log10Probability (the gene is dif ferentially expressed,
given the observed gene specific measurements ⁄ Probability
(the gene is not dif ferentially expressed, given the observed gene
specific measurements
was used in conjunction with the empirical M score (the average
difference between the 2 experimental groups) to select the best
candidate genes modulated by CPB. Gene-to-gene correlations
were calculated by using the pairwise correlation function in the
statistical package R without missing value estimation. Hierarchi-
cal clustering was used to group genes on the basis of similarity in
expression across the samples by using the Cluster software pack-
age (http://rana.lbl.gov/EisenSoftware.htm).
Category overrepresentation analysis was performed with the
Expression Analysis Systematic Explorer software, as previously
described, to identify and prioritize biologic themes within the lists
of differentially expressed genes.13 By using the 3 systems of Gene
Ontology (http://www.geneontology.org/) as categorization sys-
tems, the Expression Analysis Systematic Explorer software cal-
culates the statistical measure of overrepresentation of differen-
tially expressed genes with respect to the total number of genes
assayed and annotated within each system. This is reported as the
1-tailed Fisher exact probability corrected for multiple compari-
sons by using a bootstrap function with 10,000 random trials.13
Real-Time Reverse Transcriptase–Polymerase Chain
Reaction
Reverse transcriptase–polymerase chain reaction (RT-PCR) was
used to validate microarray data for 7 genes selected on the basis
of involvement in recognized proinflammatory and immunologic
pathways: IL-6 signal transducer (gp130), mitogen-activated pro-
tein kinase 1 (MAPK1), nuclear factor B p105 subunit (NFKB1),
st 2005
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Pplatelet selectin (SELP), tissue inhibitor of metalloproteinase 3
(TIMP3), transforming growth factor  receptor 2 (TGFBR2), and
vascular cell adhesion molecule 1 (VCAM1). Total heart RNA (3
g) from each animal was reverse transcribed with commercially
available reagents (Perkin Elmer Life Sciences, Boston, Mass).
RT-PCR was performed in duplicate by using the LightCycler
Instrument (Roche Diagnostics, Indianapolis, Ind) and SYBR Green I
fluorescence for detection. Primer sequences for the validation genes
were as follows: gp130 (5=-gtggcccagcatcaatgtgtcatcc; 3=-agaact-
tccgtactgatcctcgtgg), MAPK1 (5=-gggccgcgctacactaatctctc; 3=-ccg-
gatgatgtcattgatgccgatg), NFKB1 (5=-tcttcgactacgcggttacgggag;
3=-gatcacggccaagtgcaaaggtgtc), SELP (5=-caataagactctcacggcg-
gaggc; 3=-caggtgtagctcccaatggtctcg), TIMP3 (5=-gtacacagggctgtg-
caactttgtg; 3=-cttctgccggatgcaggcgtagtg), TGFBR2 (5=-ggagtcct-
tcaagcagacggatgtc; 3=-cagcactcggtcagtgtctcacac), VCAM1 (5=-
ggctacatccacactgacgctgag; 3=-cccttcagtagttcaatctccagatgg), GAPDH
(5=-gaccccttcattgacctcaac; 3=-cttctccatggtggtgaaga). PCR conditions
were 0.2 U of Platinum Taq (Hot Start; Invitrogen Life Tech-
nologies, Carlsbad, Calif) with supplied buffer, 1 L of SYBR
Green I (Molecular Probes, Inc, Eugene, Ore) diluted 1:1500,
0.25 mol/L of each PCR primer, 200 mol/L of each deoxyri-
bonucleoside triphosphate, and 120 ng of cDNA in a final
volume of 20 L. The amplification profile was as follows:
initial denaturation at 95°C for 2 minutes and then 40 cycles of
95°C for 5 seconds, 58°C for 10 seconds, and 72°C for 5
seconds. Tests of optimal annealing conditions and melting-
curve analysis were conducted for each set of gene-specific
primers; typically, fluorescence was acquired on channel F1 at
85°C for 2 seconds. Fluorescence curves were analyzed by
means of a second derivative method with the LightCycler
Quantification Software v1.0 (Roche Diagnostics). Relative
TABLE 1. Physiologic parameters in the experimental m
animals
Baseline 10
MAP (mm Hg)
CPB group 75 8 65
Sham group 77 13 78
CPB flow (mL · kg1 · min1)
CPB group — 157
Arterial pH
CPB group 7.40 0.03 7.39
Sham group 7.39 0.04 7.40
PaCO2 (mm Hg)
CPB group 35 2.6 40
Sham group 36 2.1 37
PaO2 (mm Hg)
CPB group 242 61 231
Sham group 256 53 225
Hemoglobin (g/dL)
CPB group 15.9 1.1 11.4
Sham group 15.2 0.9 14.2
Values are shown as means  standard deviation. MAP, Mean arterial p
at the same time point.transcript abundance (normalized to GAPDH) was determined
The Journal of Thoraciby means of comparison with 3 control samples serially diluted
10-fold. Amplicons were recovered after separation by means
of electrophoresis on a 2% Tris-borate agarose gel, cloned into
a plasmid, and sequenced to verify amplification of the correct
PCR product.
Results
Physiologic Characterization of the Rat CPB Model
There were no significant differences in hemodynamic, gas
exchange, and acid-base parameters between CPB animals
and sham control animals throughout the experimental pro-
tocol. After an initial decrease in the CPB group, differences
in hemoglobin levels between experimental groups re-
mained not significant (Table 1). Plasma cytokine levels
increased to greater than baseline values significantly more
in the CPB group than in the sham-operated animals for
both IL-6 (median [interquartile range]: 14,307 [10,006-
23,620] vs 1753 [0-2160] pg · mL1, P  .01) and IL-10
(median [interquartile range]: 770 [638-952] vs 111 [69-
182] pg · mL1, P  .01). However, the average relative
increase from baseline concentrations was larger for IL-6
(18.9-fold) than for IL-10 (5.2-fold) in CPB animals com-
pared with that seen in sham control animals, which is
consistent with a shift in circulating cytokine balance to-
ward a proinflammatory response.
Identification of Differentially Expressed Genes
Of the 2370 genes spotted on the Atlas Rat microarray, 2343
of rat CPB-treated animals and sham-operated control
Time on CPB
30 min 60 min 90 min
71  8 68  8 73  7
74  10 76 9 79  8
156 16 158 14 159  18
5 7.42 0.05 7.41 0.06 7.43  0.04
4 7.41 0.05 7.39 0.03 7.41  0.03
38 4.4 39 3.6 38  3.5
36 2.9 37 3.2 35  1.7
222 25 215 24 234  49
224 48 235 52 245  46
* 12.0 0.5* 12.1 1.0 12.3  0.7
13.9 1.1 13.6 0.8 13.4  1.1
e; CPB, Cardiopulmonary bypass. *P  .05 compared with sham animalsodel
min
 9
 11
 15
 0.0
 0.0
 3.9
 2.3
 22
 50
 0.8
 1.0
ressurunique genes were identified after querying the NCBI Uni-
c and Cardiovascular Surgery ● Volume 130, Number 2 333
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detectable hybridization levels (ie, threshold intensity at
least twice the background value) under at least one of the
2 experimental conditions and were therefore scored as a
genuine signal. After variance stabilizing transformation
and normalization, the Pearson correlation coefficients for
the pairs of replicates ranged from 0.90 to 0.94 (P  .001),
indicating a high level of reproducibility. To identify genes
differentially expressed in the heart in response to CPB, we
compared triplicate microarray hybridizations from the 2
experimental groups. A volcano plot14 of average difference
(M score) under the 2 conditions and its statistical confi-
dence (B score) for each gene is shown in Figure 2. The B
score provides a stringent threshold to prevent false-positive
identifications by taking the measurement variations into
consideration and discounting transcripts with large average
Figure 2. Volcano plot of significance against effect.
statistical significance of microarray data, as describe
score is calculated and plotted versus the average dif
using stringent statistical cutoff values, 25 downregula
in response to CPB.differences but also large variations between animals within
334 The Journal of Thoracic and Cardiovascular Surgery ● Auguexperimental groups.12 With an empiric rule of M greater
than 0.5 and B greater than 0, we identified 17 upregulated
and 25 downregulated genes, which are listed alphabetically
in Table 2. The hierarchical clustering shows that the ex-
pression profiles of the 3 bypass-treated animals belong to 2
distinct clusters (Figure 3).
Validation of mRNA Changes
We confirmed the technical quality of the microarray data in
7 selected transcripts, with fold changes in expression level
by means of real-time quantitative RT-PCR correlating
highly with fold changes in background-adjusted intensities
on the microarray (Pearson correlation coefficient, 0.946;
Figure 4). Confirmed genes correspond to the 2 clusters
identified by means of hierarchical analysis. The upregu-
lated genes include VCAM1, SELP, NF-B (NFKB1), and
sian statistical approaches were used to assess the
the “Methods” section. For each gene, a Bayesian B
ce between the 2 experimental groups (M score). By
green) and 17 upregulated genes (red) were identifiedBaye
d in
feren
ted (IL-6 signal transducer (gp130). The second cluster corre-
st 2005
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PTABLE 2. Summary of genes differentially expressed with CPB
Gene name
UniGene
Accession no. CPB Sham B score M score
Annexin III (lipocortin III) Rn.6589 6.49 0.58 7.34 0.26 0.97 0.85
ATP synthase subunit d Rn.80 9.86 0.83 9.09 0.49 0.07 0.77
Carboxylesterase 3 Rn.34885 8.56 0.44 7.96 0.17 0.46 0.60
Phosphodiesterase 4B Gb.J04563 8.33 0.67 7.56 0.6 0.19 0.77
D site albumin promoter–binding protein Rn.11274 7.10 0.21 7.80 0.17 1.39 0.70
Endoplasmic reticulum protein 29 Rn.32904 6.53 0.22 7.12 0.14 0.88 0.59
Epididymal secretory glutathione peroxidase Gb.X62404 7.59 0.34 8.14 0.25 0.36 0.55
Fatty acid–binding protein 3 Rn.32566 10.01 0.3 10.69 0.19 1.09 0.68
Fatty acid–binding protein 4 Rn.4258 8.95 0.48 9.73 0.3 0.90 0.78
Filaggrin (profilaggrin) Rn.83620 8.26 0.29 8.76 0.18 0.35 0.50
GTP-binding protein (G-alpha-i2) Rn.3036 8.44 0.24 9.00 0.3 0.48 0.56
Heat shock 27-kd protein Rn.3841 9.24 0.24 8.62 0.37 0.64 0.63
Inhibitor of DNA binding 1, helix-loop-helix protein Rn.2113 7.92 0.28 8.57 0.61 0.24 0.65
Insulin-like growth factor–binding protein 3 Rn.26369 7.67 0.32 8.28 0.15 0.79 0.61
Interferon-inducible protein 10 (IP10) Gb.U17035 9.55 1.27 7.22 1.74 1.07 2.34
Interleukin 6 receptor (IL6R) Rn.1716 7.43 0.57 6.13 1.75 0.01 1.30
Interleukin 6 signal transducer (IL6st, gp130) Rn.12138 8.76 0.22 7.82 0.61 1.24 0.94
Lysophospholipase 1 Rn.3594 6.89 0.18 7.63 0.25 1.48 0.74
Lysozyme Gb.L12458 7.23 0.14 7.85 0.22 1.01 0.62
Matrix metalloproteinase 2 (gelatinase A) Rn.6422 7.37 0.45 8.02 0.15 0.62 0.64
Mitogen-activated protein kinase 1 Rn.34914 7.65 0.46 8.17 0.16 0.13 0.52
Mitogen-activated protein kinase 3 Rn.2592 6.85 0.18 7.67 0.19 1.89 0.82
Nuclear factor B p105 subunit (NFKB1) Rn.2411 7.83 0.36 7.05 0.23 1.31 0.78
Nucleolar phosphoprotein p130 Rn.9517 8.39 0.21 7.83 0.28 0.56 0.56
Nuclear pore complex protein Rn.11398 6.59 0.63 7.26 0.48 0.09 0.67
Phospholipase A2, group IIA Rn.11346 8.21 0.62 7.60 0.01 0.21 0.61
Phospholipase C delta 1; PLC-III Gb.M20637 7.08 0.38 7.91 0.30 1.33 0.83
Preproenkephalin Rn.10015 7.56 0.67 8.16 0.17 0.03 0.60
Proteasome R-delta subunit; macropain delta;
multicatalytic endopeptidase complex delta
Gb.D10754 8.25 0.09 7.64 0.43 0.59 0.61
Protein disulfide isomerase related protein (calcium-
binding protein)
Rn.4070 7.99 0.49 8.64 0.57 0.10 0.65
Protein phosphatase type 1A Rn.37403 7.02 0.40 7.53 0.33 0.03 0.51
Ral guanine nucleotide dissociation stimulator Rn.40174 7.86 0.68 7.03 0.21 0.73 0.83
Secreted acidic cysteine-rich glycoprotein
(osteonectin)
Rn.31991 9.10 0.49 10.07 0.24 1.65 0.97
S100 calcium-binding protein A9 Rn.6703 7.27 0.85 8.12 0.57 0.18 0.85
Selectin, platelet (SELP) Rn.10012 8.21 0.45 7.20 0.25 1.85 1.00
Small inducible cytokine subfamily, member 2 Rn.10230 7.60 1.09 6.63 0.53 0.17 0.97
Sodium channel, voltage-gated, type 6, alpha
polypeptide
Rn.54541 6.78 0.61 7.63 0.25 0.92 0.85
Transforming growth factor beta receptor 2
(TGFBR2)
Rn.9954 7.13 0.15 7.68 0.57 0.08 0.55
Vascular cell adhesion molecule 1 Rn.11267 8.15 0.09 7.43 0.43 1.02 0.72
Tissue inhibitor of metalloproteinase 3 Rn.3467 7.29 0.57 7.90 0.39 0.09 0.61
Trefoil factor 2 (spasmolytic protein 1) Rn.34367 6.84 0.50 6.29 0.20 0.15 0.55
UDP-glucose dehydrogenase Rn.3967 7.75 0.10 7.17 0.22 0.91 0.58
Transcripts confirmed by means of independent real-time quantitative reverse transcriptase–polymerase chain reaction are indicated in bold type. For each
gene, the mean and standard deviation of background-adjusted normalized hybridization intensities (on variance stabilizing transformation and normal-
ization scale) in CPB and sham animals, as well as Bayesian B scores and M scores, are reported. CPB, cardiopulmonary bypass.
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sponds to genes identified as downregulated in the CPB
group and includes MAPK1, TGFBR2, and TIMP3. Al-
though most of these transcripts are known to be involved in
immune and inflammatory responses, they have not previ-
ously been reported as being differentially expressed at the
level of the myocardium in response to CPB.
Exploring Biologic Themes in Differentially Expressed
Myocardial Genes
Themes of genes upregulated with CPB, as determined by
means of overrepresentation analysis, included the follow-
ing: inflammatory response (P .015), response to external
Figure 3. Unsupervised hierarchical clustering of 42 m
from animals undergoing CPB are presented in the left
in the right 3 columns. The upper panel demonstrates
shows genes upregulated (red) compared with sham
hybridization intensity is calculated within each expe
presented relative to the calculated mean. A list of thstimulus (P  .016), response to abiotic stimulus (P 
336 The Journal of Thoracic and Cardiovascular Surgery ● Augu.029), response to biotic stimulus (P  .039), and chemo-
kine activity (P .042). Significant themes among the gene
categories downregulated with CPB include calcium ion
binding (P  .004) and nucleocytoplasmic transport (P 
.01).
Discussion
CPB causes a systemic inflammatory response, which can
lead to organ failure and increased postoperative morbidi-
ty.1 However, direct effects of CPB on the myocardium,
particularly in the absence of ischemia and reperfusion and
ardial genes differentially expressed with CPB. Data
umns, and data on sham control animals are presented
es downregulated (green), whereas the lower panel
ntrol animals. For each gene, the mean normalized
ntal group, and relative expression of each animal is
ct genes shown is further detailed in Table 2.yoc
3 col
gen
co
rime
e exacardioplegic arrest, remain poorly understood. We used a
st 2005
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Ppreviously described rat model of CPB and microarray
technology to investigate myocardial gene expression
changes in response to the stimulus of CPB. First, validity
of this unique closed-chest small-animal model of CPB in
eliciting a systemic inflammatory response was determined;
we show that rats exposed to CPB display a robust increase
in circulating levels of IL-6 and IL-10 and a shift toward a
proinflammatory response consistent with previous findings
in patients and larger animal models. Furthermore, microar-
ray-based gene expression profiling suggests that CPB in-
duces ischemia-independent transcriptional activation of
myocardial proinflammatory gene programs in the rat.
Category overrepresentation analysis identified 4 bio-
logic themes among the upregulated transcripts annotated to
main Gene Ontology biologic processes, such as inflamma-
tory response, response to external stimulus, response to
abiotic stimulus, and response to biotic stimulus. Such up-
regulated genes include neutrophil and endothelial adhesion
molecules (VCAM1 and SELP), cytokine receptors (IL6RA
and gp130), proinflammatory chemokines (IP10), and in-
flammatory enzymes (phospholipase A2). Coregulation of
these genes conceivably could be explained by activation of
the common transcriptional inducer NF-B because they all
share NF-B– binding motifs in their promoter regions.15-19
NF-B is a transcriptional regulator consisting of ho-
Figure 4. Confirmation of microarray data by means
differentially expressed with CPB. Primers for each ge
to normalize mRNA levels between samples, and value
animals versus those seen in sham-operated contro
independent experimental groups).modimers and heterodimers of 5 proteins of the Rel family,
The Journal of Thoraciincluding p65/RelA, p105/p50/NFKB1, p100/p52/NFKB2,
c-Rel, and RelB. Regulation of NF-B activation is exceed-
ingly complex, involving integration of transcriptional,
posttranscriptional, and cytoplasmic events, culminating in
nuclear translocation of NF-B dimers and binding to spe-
cific promoter elements of target genes.20 Although the
processing mechanisms that yield active p50 from the pre-
cursor p105 molecule remain to be fully elucidated, previ-
ous studies indicate that p105 gene expression directly
correlates with NF-B transcriptional activity18,21 and is
upregulated in response to different inflammatory stimuli.22
We find a strong (8.2-fold) induction of p105 gene expres-
sion in response to CPB, which is highly consistent with
other proinflammatory and immunomodulatory genes iden-
tified in our model system. Although previous studies have
demonstrated NF-B involvement in the pathophysiology
of myocardial injury associated with cardiac surgery,23 they
lacked the ability to differentiate between the roles of car-
dioplegic arrest and ischemia and reperfusion versus CPB
exposure. Our findings suggest that myocardial NF-B tran-
scriptional activity might also be influenced by ischemia-
independent mechanisms, leading to local activation of
proinflammatory cascades. However, these data do not al-
low differentiation between the roles of nonpulsatile flow
al-time quantitative RT-PCR in a subset of 7 genes
re listed in the “Methods” section. GAPDH was used
r each gene are shown as fold change in CPB-treated
mals (mean  SEM; results represent n  3 for 3of re
ne a
s fo
l aniand exposure to CPB itself in explaining the observed
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CSPchanges in myocardial gene expression, and further studies
comparing pulsatile and nonpulsatile CPB are required.
We demonstrated a significant increase in plasma IL-6
levels after CPB previously associated with circulatory dys-
regulation and myocardial dysfunction.24 IL-6 is a pleiotropic
cytokine that exerts its many actions through a heterodimeric
receptor consisting of 2 membrane-bound glycoproteins (IL-6
binding subunit [IL6RA] and IL-6 signal transducer [gp130]),
which are responsible for signal transduction and orchestration
through the JAK/STAT pathway, and shared by other cyto-
kines of the IL-6 family.25 Myocardial mRNA expression of
both IL-6 receptor subunits increased in the CPB group, mak-
ing them attractive targets for attenuation of IL-6–mediated
injury during cardiac surgery.
In addition to the observed activation of proinflammatory
genes, suppression of local anti-inflammatory activity is
suggested by the significant downregulation of myocardial
transforming growth factor receptor 2 (TGFBR2) mRNA, a
key molecule modulating various TGF-–mediated immu-
nosuppressive and immunomodulatory effects.26 Interest-
ingly, 2 novel biologic themes, namely calcium ion binding
and nucleocytoplasmic transport, have been identified
among the genes downregulated in response to CPB and
prioritized for further analysis and functional characterization.
This work has several limitations apart from those dis-
cussed above. First, our findings provide only preliminary
insight into potential pathways that are activated in a de-
fined temporal window and suggest orchestration of a pro-
grammed response to upregulate proinflammatory genes,
likely in an NF-B–dependent mechanism. Confirming the
physiologic significance of the observed transcriptional
changes requires the analysis of temporal gene expression
profiles and the association with changes in protein expres-
sion. Second, the presence of heterogeneous myocardial cell
populations in a whole-heart preparation is partially coun-
terbalanced by the fact that the biologic relevance of our
findings (the proposed physiome) might be lost in the ab-
sence of cell-cell interactions. A third limitation of this
study involves the relevance of the small-animal model to
the human clinical condition. Although hemodynamic, gas
exchange, and acid-base parameters are similar to clinical
CPB in human subjects, the higher proportion of blood–
foreign surface interaction relative to body weight in the rat
model and the use of donor rat blood to prime the CPB
circuit are current technologic limitations of rat CPB, which
could conceivably alter patterns of gene expression. Despite
this, a number of factors suspected to induce myocardial
injury during cardiac surgery, including the inflammatory
response, are replicated by this model.
Conclusion
This study represents an initial report on the use of broad-
scale genomic technology to elucidate ischemia-indepen-
338 The Journal of Thoracic and Cardiovascular Surgery ● Augudent myocardial transcriptional programs in response to
CPB-induced injury in vivo. Consistent with recent data
showing a robust systemic inflammatory response during
CPB in both human and animal models, we have shown
significant increases in circulating IL-6 and IL-10 levels
balanced toward inflammation. Furthermore, microarray-
based gene expression analysis identified a number of proin-
flammatory genes upregulated in response to CPB. The
transcription factor NF-B might be a nexus of control in
the myocardial inflammatory activation because most genes
identified appear to be regulated in an NF-B–dependent
manner. These preliminary findings, combined with future
studies superimposing ischemia-reperfusion injury with or
without CPB, should help elucidate the role played by
(dys)regulation of inflammatory pathways in the response to
myocardial injury. Studies such as these should ultimately
aid in the development of novel pharmacologic and genetic
cardioprotective strategies for cardiac surgical patients.
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